Research Head and Neck Cancer Medical Oncology
After eight years of work by a pair of University of Colorado Cancer Center leaders on a new way to attack various cancers, the next stage in their quest to bring their therapy to patients is one of nine research endeavors receiving funding from the Anschutz Acceleration Initiative (AAI).
A study is underway at Flint Animal Cancer Center in Fort Collins that has implications for human head and neck cancer. Funded by an administrative supplement for the Dog Oncology Grant Supplement (DOGS) Program issued by the National Cancer Institute (NCI) from the University of Colorado Cancer Center Head and Neck Cancer Specialized Programs of Research Excellence (SPORE), researchers speculate this study’s findings may improve outcomes for dogs and humans.
Community Head and Neck Cancer Veteran and Military Health
When the PACT Act went into effect January 1, after being signed into law in August, many U.S. veterans were able to access benefits for an expanded list of health conditions presumed to be caused by exposure to toxic substances.
Squamous cell head and neck cancers — cancers that develop in the outer layers of tissue in the oral cavity, throat, larynx, and sinonasal cavity — are the sixth most prevalent cancer worldwide. The five-year survival rate for this type of cancer is 40% to 50%, with a worse prognosis for patients with advanced disease.
Research Head and Neck Cancer Clinical Trials
Over the past decade, human papillomavirus (HPV) has increasingly been identified as a significant cause of certain head and neck cancers – for example, evidence suggests it causes 70% of oropharyngeal cancers in the United States.
Community Head and Neck Cancer
On January 2, tennis great Martina Navratilova revealed that she has been diagnosed with two unrelated cancers: stage 1 throat cancer and early-stage breast cancer.
Research Patient Care Head and Neck Cancer Clinical Trials Immunotherapy
Jane Hart is a lot of things: extremely proud mom of Shelby, daughter extraordinaire and apple of Jane’s eye. Dog mom to (deservedly spoiled) Maizy, Taco, Winnie, and Walter. Collector of Talavera pottery. Unabashed “Real Housewives of Salt Lake City” fan. A surprising 71, because she looks at least 10 years younger.
Cancer survivor – stage 4 laryngeal cancer that necessitated a tracheostomy and laryngectomy, that forced her to relearn how to breathe and talk.
Press Releases Head and Neck Cancer Cancer
A new study from researchers at the University of Colorado Anschutz Medical Campus has identified a less invasive way to treat a subset of head and neck cancers that could potentially change the standard of care for patients.
Head and Neck Cancer Cancer Oncology Immunotherapy
| A promising new study released by the University of Colorado Cancer Center suggests that recurrence of certain cancers can be significantly decreased by irradiating only a select set of lymph nodes near a tumor rather than all of them. |
Research Head and Neck Cancer Clinical Trials
A crucial challenge in cancer research is figuring out how to make immunotherapies more effective, channeling, and selectively guiding the body’s own immune responses in targeting and killing tumors.
Research Honors Head and Neck Cancer Magazine Funding
Research and treatment of head and neck cancers at the University of Colorado Cancer Center reached a new level this month with a highly competitive Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI). The SPORE was approved by NCI Scientific Program leadership for FY2021 funding; the projected starting date is July 1.
Not all cancerous tumors are created equal. Some tumors, known as “hot” tumors, show signs of inflammation, which means they are infiltrated with T cells working to fight the cancer. Those tumors are easier to treat, as immunotherapy drugs can then amp up the immune response.
Two University of Colorado Cancer Center researchers have received a five-year R01 Award for $497,893 per year from the National Institutes of Health (NIH) to study a potential new drug treatment for salivary gland cancer. The award is part of an inter-campus collaboration between Antonio Jimeno, MD, PhD, co-leader of the Developmental Therapeutics Program, and Tin Tin Su, PhD, co-leader of the Molecular and Cellular Oncology Program.
Studies have long reported that Black cancer patients have poorer outcomes than their white counterparts. But two University of Colorado Cancer Center researchers decided to investigate the data further and figure out why. What they found was that the outcome disparity was caused not by biology, but simply by differences in access to health care.
Research Head and Neck Cancer Cancer Clinical Trials
Nearly two thousand people living in Colorado will be diagnosed with head and neck cancer (HNC) in 2020. Generally, a very aggressive disease, head and neck cancer require expert care that is not widely available in community cancer clinics. However, patients that are not well-represented in clinical studies, especially Hispanic patients, are less likely to get care from centers that specialize in the disease, such as the University of Colorado Cancer Center.
Research Faculty Head and Neck Cancer
If a new anti-cancer drug shows promise in a Petri dish, often the next step is to test the drug’s effect in mice. This system tends to work well with drugs that directly target cancer, but breaks down with immunotherapies. That’s because tumors from human cancer samples can only grow in mice with suppressed immune systems. Immunotherapies activate the immune system against cancer. And in a mouse model in which the immune system has been suppressed, there is no immune system to activate against cancer.
Nearly 12,000 people will die of head and neck cancer in the United States this year and worldwide cases will exceed half a million.
Cure Today
July 12, 2024
University of Colorado Cancer Center member Dr. Steven Thorpe emphasizes the collaborative nature of treating soft tissue and bone sarcomas, highlighting the multidisciplinary efforts at CU School of Medicine's Department of Orthopedics and Children’s Hospital Colorado. He underscores the goal of not only curing the disease but also preserving function through advanced surgical techniques and modern therapies, ensuring patients maintain quality of life post-treatment. Thorpe stresses the importance of long-term outcomes, tailoring treatments to support patients’ aspirations beyond their cancer journey, especially for pediatric cases.
OncLive
July 08, 2024
CU Cancer Center member S. Lindsey Davis, MD, highlighted that the combination therapy of sapanisertib and alisertib showed marginal clinical benefit for patients with advanced solid tumors, correlative analyses suggested that apoptotic response and tumor immune cell infiltrate might influence clinical outcomes. The phase 1b study's expansion cohort indicated some positive outlying responses among patients and underscore the need for further research to tailor treatments for standout patients and explore rational combinations to enhance efficacy.
News Medical
June 19, 2024
A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.
Cancer Network
June 14, 2024
In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.
Mark Harden
